Adlai Nortye Ltd. Sponsored ADR

ANL Healthcare Biotechnology

Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023. Dividend growth for five consecutive years.

11.07 1.02 −8.44%
Market cap
$710.1M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−22.05
Beneish M
n/a
Dividend safety
n/a
Jun '26 Dec '25 Jun '25 Dec '24 Older periods
Current Ratio
9.55 0.65 1.03 1.41

+3 more quarters

Net Debt/EBITDA
0.00 0.00 0.00 0.00
Debt/Equity
0.12 (3.09) 5.59 1.05
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Book value per Share
0.00 0.00 0.00 0.00
Free Cash Flow
(15.35) (33.64) (15.12) (51.96)
Other line items

Show all line items

Columns are period end dates